Rhine R. Shen, Ph.D. - Publications

Affiliations: 
2006 University of California, Los Angeles, Los Angeles, CA 

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Shen RR, Zhou AY, Kim E, O'Connell JT, Hagerstrand D, Beroukhim R, Hahn WC. TRAF2 is an NF-κB-activating oncogene in epithelial cancers. Oncogene. 34: 209-16. PMID 24362534 DOI: 10.1038/onc.2013.543  0.44
2014 Zhu Z, Aref AR, Cohoon TJ, Barbie TU, Imamura Y, Yang S, Moody SE, Shen RR, Schinzel AC, Thai TC, Reibel JB, Tamayo P, Godfrey JT, Qian ZR, Page AN, et al. Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discovery. 4: 452-65. PMID 24444711 DOI: 10.1158/2159-8290.CD-13-0646  0.44
2013 Hagerstrand D, Tong A, Schumacher SE, Ilic N, Shen RR, Cheung HW, Vazquez F, Shrestha Y, Kim SY, Giacomelli AO, Rosenbluh J, Schinzel AC, Spardy NA, Barbie DA, Mermel CH, et al. Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. Cancer Discovery. 3: 1044-57. PMID 23764425 DOI: 10.1158/2159-8290.CD-12-0592  0.44
2013 Zhou AY, Shen RR, Kim E, Lock YJ, Xu M, Chen ZJ, Hahn WC. IKKε-mediated tumorigenesis requires K63-linked polyubiquitination by a cIAP1/cIAP2/TRAF2 E3 ubiquitin ligase complex. Cell Reports. 3: 724-33. PMID 23453969 DOI: 10.1016/j.celrep.2013.01.031  0.44
2012 Shen RR, Zhou AY, Kim E, Lim E, Habelhah H, Hahn WC. IκB kinase ε phosphorylates TRAF2 to promote mammary epithelial cell transformation. Molecular and Cellular Biology. 32: 4756-68. PMID 23007157 DOI: 10.1128/MCB.00468-12  0.44
2012 Creton S, Aardema MJ, Carmichael PL, Harvey JS, Martin FL, Newbold RF, O'Donovan MR, Pant K, Poth A, Sakai A, Sasaki K, Scott AD, Schechtman LM, Shen RR, Tanaka N, et al. Cell transformation assays for prediction of carcinogenic potential: state of the science and future research needs. Mutagenesis. 27: 93-101. PMID 21852270 DOI: 10.1093/mutage/ger053  0.44
2011 Shen RR, Hahn WC. Emerging roles for the non-canonical IKKs in cancer. Oncogene. 30: 631-41. PMID 21042276 DOI: 10.1038/onc.2010.493  0.44
2009 Hutti JE, Shen RR, Abbott DW, Zhou AY, Sprott KM, Asara JM, Hahn WC, Cantley LC. Phosphorylation of the tumor suppressor CYLD by the breast cancer oncogene IKKepsilon promotes cell transformation. Molecular Cell. 34: 461-72. PMID 19481526 DOI: 10.1016/j.molcel.2009.04.031  0.44
2009 Frank MJ, Dawson DW, Bensinger SJ, Hong JS, Knosp WM, Xu L, Balatoni CE, Allen EL, Shen RR, Bar-Sagi D, Martin GR, Teitell MA. Expression of sprouty2 inhibits B-cell proliferation and is epigenetically silenced in mouse and human B-cell lymphomas. Blood. 113: 2478-87. PMID 19147787 DOI: 10.1182/blood-2008-05-156943  0.44
2007 Boehm JS, Zhao JJ, Yao J, Kim SY, Firestein R, Dunn IF, Sjostrom SK, Garraway LA, Weremowicz S, Richardson AL, Greulich H, Stewart CJ, Mulvey LA, Shen RR, Ambrogio L, et al. Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell. 129: 1065-79. PMID 17574021 DOI: 10.1016/j.cell.2007.03.052  0.44
2007 Pelling AE, Dawson DW, Carreon DM, Christiansen JJ, Shen RR, Teitell MA, Gimzewski JK. Distinct contributions of microtubule subtypes to cell membrane shape and stability. Nanomedicine : Nanotechnology, Biology, and Medicine. 3: 43-52. PMID 17379168 DOI: 10.1016/j.nano.2006.11.006  0.44
2007 Dawson DW, Hong JS, Shen RR, French SW, Troke JJ, Wu YZ, Chen SS, Gui D, Regelson M, Marahrens Y, Morse HC, Said J, Plass C, Teitell MA. Global DNA methylation profiling reveals silencing of a secreted form of Epha7 in mouse and human germinal center B-cell lymphomas. Oncogene. 26: 4243-52. PMID 17260020 DOI: 10.1038/sj.onc.1210211  0.44
2006 Shen RR, Ferguson DO, Renard M, Hoyer KK, Kim U, Hao X, Alt FW, Roeder RG, Morse HC, Teitell MA. Dysregulated TCL1 requires the germinal center and genome instability for mature B-cell transformation. Blood. 108: 1991-8. PMID 16728701 DOI: 10.1182/blood-2006-02-001354  0.44
2003 Herling M, Teitell MA, Shen RR, Medeiros LJ, Jones D. TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood. 101: 5007-9. PMID 12576313 DOI: 10.1182/blood-2002-10-3297  0.44
2003 French SW, Malone CS, Shen RR, Renard M, Henson SE, Miner MD, Wall R, Teitell MA. Sp1 transactivation of the TCL1 oncogene. The Journal of Biological Chemistry. 278: 948-55. PMID 12421830 DOI: 10.1074/jbc.M207166200  0.44
2002 French SW, Hoyer KK, Shen RR, Teitell MA. Transdifferentiation and nuclear reprogramming in hematopoietic development and neoplasia. Immunological Reviews. 187: 22-39. PMID 12366680 DOI: 10.1034/j.1600-065X.2002.18703.x  0.44
2002 French SW, Shen RR, Koh PJ, Malone CS, Mallick P, Teitell MA. A modeled hydrophobic domain on the TCL1 oncoprotein mediates association with AKT at the cytoplasmic membrane. Biochemistry. 41: 6376-82. PMID 12009899 DOI: 10.1021/bi016068o  0.44
Show low-probability matches.